Article Text

Download PDFPDF
Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database
  1. U A Walker1,
  2. A Tyndall1,
  3. L Czirják2,
  4. C Denton3,
  5. D Farge-Bancel4,
  6. O Kowal-Bielecka5,
  7. U Müller-Ladner6,
  8. C Bocelli-Tyndall1,
  9. M Matucci-Cerinic7,
  10. EUSTAR Co-authors*
  1. 1Department of Rheumatology, Basle University, Felix Platter Spital, Basel, Switzerland
  2. 2University of Pécs, Department of Immunology and Rheumatology, Pécs, Hungary
  3. 3Centre for Rheumatology, Royal Free and University College London Medical School, London, UK
  4. 4Department of Internal Medicine, Hospital Saint Louis, Paris, France
  5. 5Department of Rheumatology, Medical University of Bialystok, Biolystok, Poland
  6. 6Department of Rheumatology Kerckhoff Klinik, Bad Nauheim, Germany
  7. 7Department of Internal Medicine, Section of Rheumatology, University of Florence, Italy
  1. Correspondence to:
    U A Walker
    Department of Rheumatology, Basle University, Felix Platter Spital, Burgfelderstrasse 101, Basel 4012, Switzerland;ulrich.walker{at}


Background: Systemic sclerosis (SSc) is a multisystem autoimmune disease, which is classified into a diffuse cutaneous (dcSSc) and a limited cutaneous (lcSSc) subset according to the skin involvement. In order to better understand the vascular, immunological and fibrotic processes of SSc and to guide its treatment, the EULAR Scleroderma Trials And Research (EUSTAR) group was formed in June 2004.

Aims and methods: EUSTAR collects prospectively the Minimal Essential Data Set (MEDS) on all sequential patients fulfilling the American College of Rheumatology diagnostic criteria in participating centres. We aimed to characterise demographic, clinical and laboratory characteristics of disease presentation in SSc and analysed EUSTAR baseline visits.

Results: In April 2006, a total of 3656 patients (1349 with dcSSc and 2101 with lcSSc) were enrolled in 102 centres and 30 countries. 1330 individuals had autoantibodies against Scl70 and 1106 against anticentromere antibodies. 87% of patients were women. On multivariate analysis, scleroderma subsets (dcSSc vs lcSSc), antibody status and age at onset of Raynaud’s phenomenon, but not gender, were found to be independently associated with the prevalence of organ manifestations. Autoantibody status in this analysis was more closely associated with clinical manifestations than were SSc subsets.

Conclusion: dcSSc and lcSSc subsets are associated with particular organ manifestations, but in this analysis the clinical distinction seemed to be superseded by an antibody-based classification in predicting some scleroderma complications. The EUSTAR MEDS database facilitates the analysis of clinical patterns in SSc, and contributes to the standardised assessment and monitoring of SSc internationally.

  • ACA, anticentromere autoantibody
  • ACR, American College of Rheumatology
  • CK, creatine kinase
  • dcSSc, diffuse cutaneous systemic sclerosis
  • EUSTAR, EULAR Scleroderma Trials And Research
  • lcSSc, limited cutaneous systemic scerosis
  • PAH, pulmonary artery hypertension (assessed by echocardiography)
  • SSc, sytemic sclerosis

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.